I M Svane

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint Clinical application of dendritic cells in cancer vaccination therapy
    Inge Marie Svane
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    APMIS 111:818-34. 2003
  2. doi request reprint Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
    Inge Marie Svane
    Department of Oncology, Center for Cancer Immune Therapy, Copenhagen University Hospital at Herlev, Denmark
    Vaccine 26:4716-24. 2008
  3. ncbi request reprint Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
    Inge Marie Svane
    Department of Oncology, Herlev University Hospital, Herlev, Denmark
    Cancer Immunol Immunother 53:633-41. 2004
  4. ncbi request reprint [Dendrite cell-based cancer vaccines--clinical application]
    Inge Marie Svane
    Amtssygehuset i Herlev, Onkologisk og Haematologisk Afdeling, og Københavns Universitet, Panum Instituttet, Herlev
    Ugeskr Laeger 168:1415-20. 2006
  5. ncbi request reprint Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
    Inge Marie Svane
    Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
    Cancer Immunol Immunother 56:1485-99. 2007
  6. ncbi request reprint Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study
    Inge M Svane
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    Acta Oncol 41:675-83. 2002
  7. ncbi request reprint Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination
    I M Svane
    Center for Cancer Immune Therapy, Department of Haematology, Copenhagen University Hospital, Herlev, Denmark
    Scand J Immunol 66:465-75. 2007
  8. ncbi request reprint The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice
    I M Svane
    Department of Oncology, Herlev Hospital University of Copenhagen, Denmark
    Med Oncol 16:223-38. 1999
  9. ncbi request reprint Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination
    A E Pedersen
    Laboratory of Cellular Immunology, Department of Medical Anatomy A, University of Copenhagen, Copenhagen, Denmark
    Scand J Immunol 61:147-56. 2005
  10. ncbi request reprint Characterization of monocyte-derived dendritic cells maturated with IFN-alpha
    I M Svane
    Department of Oncology, Herlev University Hospital, Denmark
    Scand J Immunol 63:217-22. 2006

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Clinical application of dendritic cells in cancer vaccination therapy
    Inge Marie Svane
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    APMIS 111:818-34. 2003
    ....
  2. doi request reprint Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
    Inge Marie Svane
    Department of Oncology, Center for Cancer Immune Therapy, Copenhagen University Hospital at Herlev, Denmark
    Vaccine 26:4716-24. 2008
    ..Finally, prior to immunotherapy a higher percentage of both CD28 and CD27 positive CD8naïve/early effector memory T cells were present in chemotherapy-treated patients...
  3. ncbi request reprint Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
    Inge Marie Svane
    Department of Oncology, Herlev University Hospital, Herlev, Denmark
    Cancer Immunol Immunother 53:633-41. 2004
    ..An independent clinical effect of repeated administration of DCs and IL-2 can not of course be excluded; further studies are necessary to answer these questions...
  4. ncbi request reprint [Dendrite cell-based cancer vaccines--clinical application]
    Inge Marie Svane
    Amtssygehuset i Herlev, Onkologisk og Haematologisk Afdeling, og Københavns Universitet, Panum Instituttet, Herlev
    Ugeskr Laeger 168:1415-20. 2006
    ..The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach...
  5. ncbi request reprint Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
    Inge Marie Svane
    Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
    Cancer Immunol Immunother 56:1485-99. 2007
    ..In conclusion, a significant fraction of breast cancer patients obtained SD during p53-targeting DC therapy. Data encourage initiation of a randomized trial in p53 positive patients evaluating the impact on progression free survival...
  6. ncbi request reprint Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study
    Inge M Svane
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    Acta Oncol 41:675-83. 2002
    ..Until now, high-dose chemotherapy has not proven superior to conventional-dose adjuvant chemotherapy, therefore it is necessary in the future to focus on well-designed randomized studies...
  7. ncbi request reprint Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination
    I M Svane
    Center for Cancer Immune Therapy, Department of Haematology, Copenhagen University Hospital, Herlev, Denmark
    Scand J Immunol 66:465-75. 2007
    ..In conclusion, the study demonstrates that natural as well as vaccine induced specific immunity present prior to HD was regained after stem cell transplantation, hence identifying a possible window for future vaccination trials...
  8. ncbi request reprint The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice
    I M Svane
    Department of Oncology, Herlev Hospital University of Copenhagen, Denmark
    Med Oncol 16:223-38. 1999
    ..In this review, we discuss the difficulties facing immunotherapy when conclusions are drawn from the presented observations and hypotheses...
  9. ncbi request reprint Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination
    A E Pedersen
    Laboratory of Cellular Immunology, Department of Medical Anatomy A, University of Copenhagen, Copenhagen, Denmark
    Scand J Immunol 61:147-56. 2005
    ..These data suggest that patient-derived DC are more differentiated but are less sensitive to maturation-inducing agents than DC obtained from healthy individuals...
  10. ncbi request reprint Characterization of monocyte-derived dendritic cells maturated with IFN-alpha
    I M Svane
    Department of Oncology, Herlev University Hospital, Denmark
    Scand J Immunol 63:217-22. 2006
    ..However, an increase in DC allogeneic T-cell stimulatory capacity was observed. These data suggest that IFN-alpha has a potential as a maturation agent used in DC-based cancer vaccine trials, but not as a single reagent...
  11. ncbi request reprint Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method
    I M Svane
    Department of Oncology, Herlev Hospital University of Copenhagen, DK 2730 Herlev, Denmark
    Bone Marrow Transplant 29:659-66. 2002
    ..These data indicate that introduction of a preventive cancer vaccination in combination with intensive chemotherapy may be a realistic treatment option...
  12. doi request reprint Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial
    Annika Berntsen
    Department of Oncology Section, Center for Cancer Immunotherapy, Herlev Hospital, Herlev, Denmark
    J Immunother 31:771-80. 2008
    ..Antigen-specific immune responses were observed in a subset of the treated patients...
  13. pmc Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma
    M K Brimnes
    Department of Haematology, Herlev Hospital, Herlev Ringvej, University of Copenhagen, Herlev, Denmark
    Clin Exp Immunol 144:76-84. 2006
    ..Finally, the analysis of samples following chemotherapy and transplantation demonstrated an increased expression of HLA molecules, suggesting that this time-point is optimal for harvest and use in vaccination...
  14. doi request reprint Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate
    A Soleimani
    Department of International Health, Immunology and Microbiology, The Panum Institute, University of Copenhagen, Denmark
    Scand J Immunol 70:481-9. 2009
    ..An increase in IL-12, IL-17 and IL-18 serum concentrations was observed during vaccination but no difference between patients with SD and PD was observed. IL-10 or IL-15 was not measurable in serum...
  15. ncbi request reprint Cellular based cancer vaccines: type 1 polarization of dendritic cells
    M Hansen
    Center for Cancer Immune Therapy CCIT, Department of Hematology, 54P4, Copenhagen University Hospital, Herlev, Denmark
    Curr Med Chem 19:4239-46. 2012
    ..In the current review, we discuss optimal design of DC maturation focused on pre-clinical as well as clinical results from standard and polarized dendritic cell based cancer vaccines...
  16. doi request reprint Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma
    M K Brimnes
    Center for Cancer Immune Therapy, Department of Haematology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    Scand J Immunol 72:540-7. 2010
    ..Taken together, our results illustrate that, both mDC, pDC, Treg cells and MDSC are affected in patients with MM underlining the fact that the immune system is dysregulated as a consequence of the disease...
  17. ncbi request reprint Impaired circulating myeloid DCs from myeloma patients
    T H Do
    Department of Hematology, Herlev Hospital, University of Copenhagen Herlev, Denmark
    Cytotherapy 6:196-203. 2004
    ....
  18. ncbi request reprint CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53
    Rikke Baek Sørensen
    Center for Cancer Immune Therapy, Department of Hematology, University Hospital Herlev, Herlev Ringvej, Denmark
    Clin Cancer Res 15:1543-9. 2009
    ..This study aimed to examine CD8 T-cell reactivity in breast cancer patients against cyclin B1-derived peptides restricted by the human leukocyte antigen (HLA)-A2 molecule...
  19. doi request reprint Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients
    Redas Trepiakas
    Center for Cancer Immune Therapy CCIT, Department of Hematology, Herlev University Hospital, Denmark
    Vaccine 26:2824-32. 2008
    ..Also, this study indicates the necessity for further investigation of correlation between in vitro DC parameters and their in vivo efficacy in clinical vaccination trials...
  20. doi request reprint RhoC a new target for therapeutic vaccination against metastatic cancer
    Lynn Wenandy
    Center for Cancer Immune Therapy CCIT, Department of Hematology, Herlev University Hospital, 2730, Herlev, Denmark
    Cancer Immunol Immunother 57:1871-8. 2008
    ..Moreover, RhoC-specific T cells show cytotoxic potential against HLA-matched cancer cells of different origin. Thus, RhoC may serve as an important and widely applicable target for anti-cancer immunotherapeutic strategies...
  21. doi request reprint Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2
    J Bjoern
    Center for Cancer Immune Therapy, Department of Haematology, Copenhagen University Hospital, Herlev, Denmark
    Scand J Immunol 73:222-33. 2011
    ..These findings emphasize the need for strategies to effectively eliminate Treg cells to optimize the clinical effectiveness of cancer immunotherapy...
  22. doi request reprint The immunogenicity of the hTERT540-548 peptide in cancer
    Lynn Wenandy
    Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark
    Clin Cancer Res 14:4-7. 2008
    ..Hence, our data support the findings that hTERT540 peptide is presented by human tumors and can be a target for CTL-mediated tumor lysis...
  23. pmc The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase
    Rikke Baek Sørensen
    Center for Cancer Immune Therapy CCIT, Department of Hematology, Herlev University Hospital, Herlev, Denmark
    PLoS ONE 4:e6910. 2009
    ..In the present study, we tested the notion whether IDO itself may be subject to immune responses...
  24. ncbi request reprint Therapeutic dendritic cell vaccination of patients with renal cell carcinoma
    Annika Berntsen
    Department of Oncology, Herlev University Hospital, Herlev, Denmark
    Eur Urol 50:34-43. 2006
    ..Dendritic cell (DC) vaccination against cancer is a new specific immunotherapeutic approach given with either therapeutic or adjuvant intent. We provide a review of DC vaccination as a treatment for metastatic renal cell carcinoma (RCC)...
  25. doi request reprint Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin
    Anna Tsakiri
    Department of Neurology, Glostrup University Hospital, 57 Ndr Ringvej, Glostrup DK 2600, Denmark
    Exp Neurol 221:320-8. 2010
    ..The results from these in vitro assays suggest potential beneficial inhibitory effects of Simvastatin in the inflammation in ON and early MS, but we need more clinical trials to confirm it...
  26. pmc Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients
    Mads Hald Andersen
    Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark
    J Clin Invest 119:2245-56. 2009
    ..Identification of potent antigen-specific CD8+ Tregs may open new avenues for therapeutic interventions in both autoimmune diseases and cancer...
  27. doi request reprint Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2
    Annika Berntsen
    Department of Oncology, Copenhagen University Hospital at Herlev, Denmark
    J Immunother 33:425-34. 2010
    ..Also, adjuvant IL-21 administration may lead to immune enhancement without simultaneous induction of Treg cells...
  28. pmc Cancer treatment: the combination of vaccination with other therapies
    Mads Hald Andersen
    Department of Hematology, Center for Cancer Immune Therapy CCIT, Herlev University Hospital, 54P4, Herlev Ringvej 75, 2730 Herlev, Denmark
    Cancer Immunol Immunother 57:1735-43. 2008
    ..These combinations should be based on current knowledge not only regarding the biology of the cancer cell per se, but also considering how treatment may influence the malignant cell population as well as the immune system...
  29. pmc Therapeutic cancer vaccines in combination with conventional therapy
    Mads Hald Andersen
    Center for Cancer Immune Therapy CCIT, Department of Hematology, Copenhagen University Hospital, 2730 Herlev, Denmark
    J Biomed Biotechnol 2010:237623. 2010
    ..Proteins associated with the malignant phenotype can be targeted to specifically target cancer cells, but proteins targeted by immunotherapy may also simultaneously target cancer cells as well as suppressive cells in the tumor stroma...
  30. doi request reprint Functional characterization of Foxp3-specific spontaneous immune responses
    S K Larsen
    Center for Cancer Immune Therapy CCIT, Department of Hematology, 54P4, Copenhagen University Hospital, Herlev, Denmark
    Leukemia 27:2332-40. 2013
    ..Consequently, induction of Foxp3-specific cytotoxic T-cell responses appears as an attractive tool to boost spontaneous or therapeutically provoked immune responses, for example, for the therapy of cancer. ..
  31. doi request reprint Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function
    Redas Trepiakas
    Center for Cancer Immune Therapy CCIT, Department of Hematology, Herlev University Hospital, Denmark
    Vaccine 27:2213-9. 2009
    ..Our observations suggest that IFN-alpha could be included in maturation protocols for clinical grade DCs used for immunotherapy against cancer and should be included if DCs are used for CD8+ T-cell stimulation in vitro...
  32. ncbi request reprint The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines
    Rikke Baek Sørensen
    Department of Hematology, Center for Cancer Immune Therapy CCIT, Herlev University Hospital, Herlev, Denmark
    Cancer Immunol Immunother 58:665-75. 2009
    ..Thus, the very frequently used MART-1 epitope was not expressed on the surface of many melanoma cell lines. Our data emphasize that the selected tumor antigens and/or epitopes are critical for the outcome of anti-cancer immunotherapy...
  33. ncbi request reprint Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression
    A M Engel
    Institute of Medical Microbiology and Immunology, University of Copenhagen, Panum Institute, Denmark
    APMIS 104:629-39. 1996
    ....
  34. doi request reprint Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
    Lotte Engell-Noerregaard
    Department of Oncology, Herlev Hospital, Herlev, Denmark
    Cancer Immunol Immunother 58:1-14. 2009
    ....
  35. ncbi request reprint The universal character of the tumor-associated antigen survivin
    Mads Hald Andersen
    Center for Cancer Immunotherapy, Department of Hematology, Herlev University Hospital, Herlev, Denmark
    Clin Cancer Res 13:5991-4. 2007
    ..Data from several ongoing phase I/II trials targeting survivin for patients with advanced cancer will provide further information about this idea...
  36. ncbi request reprint A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis
    Rikke Baek Sørensen
    Centre for Cancer Immune Therapy CCIT, Department of Hematology, Herlev University Hospital, Herlev, Denmark
    Cancer Biol Ther 7:1885-7. 2008
    ..e., breast cancer, colon cancer and melanoma cells. The data support the notion that survivin may serve as a universal target antigen for anti-cancer immunotherapy...
  37. doi request reprint Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential
    Ozcan Met
    Department of Hematology, Center for Cancer Immune Therapy CCIT, University Hospital Herlev, Herlev Ringvej 75, Copenhagen 2730, Herlev, Denmark
    Mol Biotechnol 40:151-60. 2008
    ..These findings support the concept of mRNA transfection of DCs after maturation and also highlight the possibility to use long electrical pulses for further improvement of the immune responses by mRNA-transfected DCs...
  38. doi request reprint Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients
    Pia Kvistborg
    Dandritt Biotech, Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen, Denmark
    Hum Immunol 69:266-72. 2008
    ..The characterized CYP240 peptide presented herein opens the avenue for more broader recruitment of patients in vaccination trials targeting CYB1B1...
  39. ncbi request reprint Identification of novel survivin-derived CTL epitopes
    Sine Reker
    Tumor Immunology Group, Division of Canter Biology, Danish Cancer Society, Copenhagen, Denmark
    Cancer Biol Ther 3:173-9. 2004
    ..Additionally, the collective targeting of several restriction elements is likely to decrease the risk of immune escape by HLA-allele loss...
  40. ncbi request reprint Immunogenicity of Bcl-2 in patients with cancer
    Mads Hald Andersen
    Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Demmark
    Blood 105:728-34. 2005
    ..Thus, Bcl-2 may serve as an important and widely applicable target for anticancer immunotherapeutic strategies (eg, in the combination with conventional radiotherapy and chemotherapy)...
  41. ncbi request reprint Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients
    Anders Meier
    Tumor Immunology Group, Danish Cancer Society, Institute for Cancer Biology, Strandboulevarden 49, 2100 Copenhagen, Denmark
    Cancer Immunol Immunother 54:219-28. 2005
    ..Hence, these epitopes represent potential target structures for future therapeutic vaccinations against cancer, possibly appropriate for strategies that combine vaccination and chemotherapy; i.e., paclitaxel treatment...
  42. ncbi request reprint [High dose chemotherapy versus conventional chemotherapy in metastasing breast cancer. An analysis of a systematic Cochrane review]
    Dorte Lisbet Nielsen
    Onkologisk afdeling, Amtssygehuset i Herlev
    Ugeskr Laeger 166:4145-7. 2004
  43. ncbi request reprint [High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy in primary breast cancer. An analysis of a systematic Cochrane review]
    Dorte Lisbet Nielsen
    Onkologisk afdeling, Amtssygehuset i Herlev
    Ugeskr Laeger 166:4148-50. 2004
  44. ncbi request reprint Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient
    Rikke Baek Sørensen
    Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, 2100 Strandboulevarden 49, Copenhagen, Denmark
    Cancer Immunol Immunother 56:527-33. 2007
    ..Finally, ex vivo-isolated leukemia cells, but not non-malignant B and T cells are killed by Bcl-X(L) specific T cells. Our data underline Bcl-X(L) as an universal tumor antigen widely applicable in specific anticancer immunotherapy...
  45. ncbi request reprint HLA-B35-restricted immune responses against survivin in cancer patients
    Sine Reker
    Tumor Immunology Group, Division of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Int J Cancer 108:937-41. 2004
    ..The characterization of these epitopes allows more patients can be included in the ongoing peptide-based survivin vaccination trials against cancer...